What does the evidence say about Saw Palmetto Urinary Symptoms Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Saw Palmetto Urinary Symptoms Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - This systematic review assessed the potential effectiveness and safety of Serenoa repens (saw palmetto) for benign prostatic disorders, mainly benign prostatic hyperplasia and associated lower urinary tract symptoms. [Schwartzmann I (2026); evidence level 1] - repens was associated with improvements in symptom severity (International Prostate Symptom Score) in several trials, with variable effects on urinary flow, post-void residual volume, and patient-reported quality of life. [Schwartzmann I (2026); evidence level 1] - Following PRISMA guidance (PROSPERO: CRD420251032255), we searched PubMed, Cochrane and ScienceDirect for human studies from January 2020 to May 2025. [Schwartzmann I (2026); evidence level 1] - Conclusions : Although this study was a pilot study with a limited cohort, these findings provide preliminary evidence for the use of SAGX as a functional ingredient for supporting urinary health in men with LUTS. [Kim EY (2026); evidence level 2] - Background: Lower urinary tract symptoms (LUTS) are prevalent among aging men and negatively affect quality of life. [Kim EY (2026); evidence level 2] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.